

(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041274 A1(51) International Patent Classification⁷: A61K 31/4192, A61P 3/00, C07D 249/18, 405/06(21) International Application Number:
PCT/US2003/035427(22) International Filing Date:
4 November 2003 (04.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/423,819 5 November 2002 (05.11.2002) US

(71) Applicant (for all designated States except US): ARENA PHARMACEUTICALS, INC. [US/US]; 6166 Nancy Ridge Drive, San Diego, CA 92121-3223 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SEMPLER, Graeme [GB/US]; 15920 Camino Codorniz, San Diego, CA

92127 (US). SKINNER, Philip [GB/US]; 1222 Oliver Avenue #2, San Diego, CA 92109 (US). CHERRIER, Martin [US/US]; 4179 3rd Avenue, Apt. 316, San Diego, CA 92103 (US). WEBB, Peter [US/US]; 10972 West Ocean Air Drive, Apt. 291, San Diego, CA 92130 (US). TAMURA, Susan, Yoshiko [US/US]; 8745 Wescott Court, San Diego, CA 92129 (US).





(74) Agents: SPRUCE, Lyle et al.; Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, CA 92121-3223 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF

Screening Data for Nicotinic Acid and 1-Isopropyl-1H-Benzotriazole-5-Carboxylic Acid in cAMP Assays



(57) Abstract: The present invention relates to certain benzotriazole carboxylic acid or ester derivatives of Formula (I), pharmaceutically acceptable salts and solvates thereof, which exhibit useful pharmaceutical properties, for example, as agonists for the GPCR referred to as hRUP38. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of -glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.